Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3137Neoplasms 2472Carcinoma, Non-Small-Cell Lung 1886Prostatic Neoplasms 1635Colorectal Neoplasms 1435Lung Neoplasms 1308Multiple Myeloma 939Neoplasm Metastasis 928Leukemia, Myeloid, Acute 884Pancreatic Neoplasms 856Ovarian Neoplasms 810Melanoma 791Carcinoma, Hepatocellular 742Stomach Neoplasms 648Brain Neoplasms 641Recurrence 640Squamous Cell Carcinoma of Head and Neck 639Head and Neck Neoplasms 612Glioblastoma 573Lymphoma 550Uterine Cervical Neoplasms 545Triple Negative Breast Neoplasms 513Precursor Cell Lymphoblastic Leukemia-Lymphoma 509Carcinoma, Renal Cell 504Hematologic Neoplasms 466Endometrial Neoplasms 466Urinary Bladder Neoplasms 462Colonic Neoplasms 446Lymphoma, Non-Hodgkin 439Sarcoma 436

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Serous Adenocarcinoma × 1 year × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡